The CEO of Lyndra Therapeutics describes the company's technology that turns daily pills into weekly ones - and potentially longer

blonca9
Dec 9, 2024
1 min read

Jessica Ballinger describes the science behind this and how an extended release format can improve health outcomes. Plus, the progress Lyndra has made developing a risperidone based product, and other areas this might be used for.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

The CEO of Lyndra Therapeutics describes the company's technology that turns daily pills into weekly ones - and potentially longer

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight